利妥木单抗与ECX方案在胃癌三期研究中的药代动力学相互作用评估
本研究为三期双盲安慰剂对照研究,纳入609例胃癌患者,评估利妥木单抗与表柔比星、顺铂和卡培他滨(ECX)之间是否存在药代动力学药物相互作用。结果显示ECX的Cmax和AUC几何均值比接近1.0,利妥木单抗观测浓度与群体药代动力学模型预测值相似,提示两者无药代动力学相互作用。
要点
- 利妥木单抗与ECX联用不影响ECX的Cmax和AUC。
- ECX联用不影响利妥木单抗的暴露量。
- 两者之间无基于药代动力学的药物相互作用。
核心结论
- 利妥木单抗与ECX之间不存在基于药代动力学的药物相互作用。
研究设计与样本
- 三期双盲安慰剂对照研究,纳入609例胃癌患者,利妥木单抗15 mg kg-1、表柔比星50 mg m-2、顺铂60 mg m-2每三周静脉给药,卡培他滨625 mg m-2每日两次口服。
主要发现
- ECX在有无利妥木单抗时的血浆浓度相似,Cmax和AUC的几何均值比接近1.0。
- 利妥木单抗观测血清浓度与基于群体药代动力学模型的预测值相似。
关键数值与推荐
- ECX的Cmax和AUC几何均值比接近1.0,提示利妥木单抗不影响ECX药代动力学。
- 预测校正视觉预测检查显示利妥木单抗观测浓度与模型预测值相似,提示ECX不影响利妥木单抗暴露。
临床怎么用
- 临床联用利妥木单抗与ECX方案时,无需基于药代动力学相互作用进行调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Rilotumumab is a fully human monoclonal antibody investigated for the treatment of MET-positive gastric cancer. The aim of this study was to evaluate the potential pharmacokinetic (PK)-based drug-drug interaction (DDI) between rilotumumab and epirubicin (E), cisplatin(C) and capecitabine (X). METHODS: This was a Phase 3 double-blind, placebo-controlled study, in which rilotumumab, epirubicin and cisplatin were administered intravenously at 15 mg kg-1 , 50 mg m-2 , and 60 mg m-2 Q3W, respectively, while capecitabine was given orally at 625 mg m-2 twice daily. Rilotumumab PK samples were taken at pre-dose and at the end-of-infusion from all patients in cycles 1, 3, 5 and 7. ECX PK samples were taken in cycle 3 from patients who participated in the intensive PK assessment. ECX PK was assessed by non-compartmental (NCA) analyses and PK parameters were compared between two arms. Rilotumumab PK was assessed by comparing the observed rilotumumab serum concentrations with model-predicted concentrations using a population PK model developed from previous Phase 1 and Phase 2 studies. RESULTS: The study enrolled 609 patients. ECX plasma concentrations in the presence and absence of rilotumumab were similar, as demonstrated by the geometric mean ratios for Cmax and AUC, which were close to 1.0, suggesting ECX PK was not affected by co-administration of rilotumumab. The observed rilotumumab serum concentrations were similar to the values predicted by population PK modelling on the basis of a prediction-corrected visual predictive check, indicating rilotumumab exposure was not affected by co-administration of ECX. CONCLUSIONS: The results suggest lack of PK-based DDI between rilotumumab and ECX.
引用
- Zhang Y, Kuchimanchi M, Zhu M, et al. Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer. Br J Clin Pharmacol. 2016. PMID: 27966237. doi:10.1111/bcp.13179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。